BioPharmSignal logoBioPharmSignal

Biotech News

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

Lineage Cell Therapeutics (LCTX)Lineage Cell TherapeuticsCompany update

U.S. Patent No. 12,692,476 Has an Expected Expiration Date of June 9, 2043 CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 8, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for

Related news

LCTXLineage Cell Therapeutics2026-11-05 13:00 EST

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

IRIXIRIDEX2026-10-05 11:00 EST

Iridex Completes Relocation of Manufacturing Facility to San Jose, California

OTLKOutlook2026-09-11 11:00 EST

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

OTLKOutlook2026-08-06 12:45 EST

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

RHHBYRoche Holdings AG2026-08-20 15:45 EST

Roche’s US subsidiary Genentech announces manufacturing expansion in the United States

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

OCSOculis2026-08-10 07:30 EST

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

LENZLenz Therapeutics Inc2026-08-04 20:05 EST

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

View all latest news

Lineage Cell Therapeutics

Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic...

Recent company news

LCTXLineage Cell Therapeutics2026-11-05 13:00 EST

Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

LCTXLineage Cell Therapeutics2026-10-29 12:00 EST

Lineage Provides Update on ReSonance® Program for Hearing Loss

LCTXLineage Cell Therapeutics2026-09-08 12:00 EST

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Stock data

Close
0.98 USD
Market cap
301.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States